George Fotiades
Executive Chairman & Co-Founder
George Fotiades is a recognized chief executive who has successfully led complex companies through significant change. His 40-year career has spanned several industry verticals including pharmaceutical services, healthcare distribution and supply chain solutions, packaging, medical devices, dental products and consumer healthcare.
Prior to Elio Health, George served as CEO of Cantel Medical, a leader in healthcare infection prevention solutions. During his tenure at Cantel, George restructured the organization, drove significant enhancement of its commercial focus, and completed a $775 million acquisition to become the leader in dental office infection prevention. In June 2021, George led the significant strategic sale of Cantel to Steris Corporation in June 2021 for $4.6B, a ~17x EBITDA multiple. Earlier, George joined Diamond Castle Holdings in 2007, a mid-market private equity firm which later merged into Five Arrows Capital Partners, part of Rothschild Merchant Banking. George and his health care team completed 14 transactions representing $1.9 billion in value. The combined investments yielded a 3.0x multiple of invested capital and a 26% IRR.
​
Until mid-2006, George was President and COO of Cardinal Health. He came to Cardinal Health in 1998 with the acquisition of R.P. Scherer, a leading global developer of drug delivery technologies. By integrating over ten acquired businesses, George created Cardinal’s Pharmaceutical Technologies & Services division, a leading provider of contract pharmaceutical development, manufacturing and packaging services. This division was later sold to Blackstone and is, today, Catalent (NYSE: CTLT). George served as chairman of Catalent prior to its IPO.
Before joining Cardinal Health, George gained 20 years of marketing and general management experience including 11 years with Procter & Gamble.
​
George serves on the boards of AptarGroup (NYSE: ATR), the leading global supplier of dispensing systems for consumer and pharmaceutical products, ProLogis (NYSE: PLD), the leading global provider of distribution facilities and services, Curia Global, a leading contract research, development and manufacturing organization and Inceptor Bio, a biotech company advancing cell therapies in oncology.
​
George holds a bachelor's degree in economics from Amherst College and a master's degree from Kellogg School of Management at Northwestern.
Seth Yellin
President & Co-Founder
Seth has over 25 years of experience in the healthcare industry with a focus on M&A, strategy, and business development.
​
Prior to Elio Health, Seth was Executive Vice President, Chief Growth Officer for Cantel Medical, where he oversaw Cantel’s corporate strategy, M&A and organic growth initiatives. In this role he led the execution of 24 acquisitions and two dispositions across the Cantel portfolio, culminating in the sale of Cantel for $4.6 billion to Steris Corporation in June 2021. His efforts were focused on strategic planning, portfolio enhancement through the addition of new products and services, international expansion, and the entry into new markets and categories. During his 10-year tenure at Cantel, total company sales grew at over 13% annually, from $375 million to over $1.2 billion while profitability grew by over 20% annually.
​
Prior to joining Cantel, Seth spent 10 years on Wall Street as both an investor and advisor. He was a senior analyst leading portfolio coverage of medical devices and the life science tools sectors at Citadel Asset Management and Millennium Management and was an M&A investment banker at UBS. Seth began his career in outpatient provider services focused on physician practice acquisitions and corporate strategy.
​
Seth received his undergraduate degree from Princeton University and received an MBA degree from The Wharton School at the University of Pennsylvania.